The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer’s disease: a meta-analysis of randomized controlled trials.
Saved in:
| Title: | The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer’s disease: a meta-analysis of randomized controlled trials. |
|---|---|
| Authors: | O'Mara, Ashley (AUTHOR), Mody, Bhakti Pradip (AUTHOR), Mammi, Marco (AUTHOR), Simjian, Thomas (AUTHOR), Ghattas, Kyrellos (AUTHOR), Kaliki, Srilekha (AUTHOR), Le, Ngoc Phuong Mai (AUTHOR), Liew, Aaron (AUTHOR), Migliore, Mattia (AUTHOR), Mekary, Rania A. (AUTHOR) |
| Source: | Neurological Sciences. Jan2026, Vol. 47 Issue 1, p1-11. 11p. |
| Abstract: | Background: Currently, the cognitive impact of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains unclear in non-diabetic patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI), despite their widespread use for type 2 diabetes. This meta-analysis summarized cognitive outcomes from randomized controlled trials (RCTs) of GLP-1 RAs in non-diabetic patients with AD or MCI. Methods: PubMed, Cochrane Library, and Embase were searched for studies through October 27, 2024. Pooled standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated using random-effects models. Sensitivity analyses addressed variations in cognitive assessment methodologies. Between-study heterogeneity was evaluated using the I² index. Results: Four RCTs comprising 112 patients (61 placebo, 51 treatment) were included. For cognitive tests where higher scores indicate better outcomes, no significant difference was observed between GLP-1 RA and placebo groups (pooled SMD: -0.10, 95% CI: -0.53, 0.34; I² = 23.9%). Sensitivity analyses yielded consistent results. Analysis of the Alzheimer’s Disease Assessment Scale–Cognitive subscale from two studies, where lower scores indicate better outcomes, similarly showed no significant treatment effect (SMD: 0.07, 95% CI: -0.47, 0.62; I² = 0%). Conclusion: There was no evidence that GLP-1 RAs improved cognitive outcomes compared to placebo in non-diabetic patients with AD or MCI. Further research is needed to clarify their neuroprotective potential and explore alternative therapeutic strategies for cognitive decline. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 190837769 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer’s disease: a meta-analysis of randomized controlled trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22O'Mara%2C+Ashley%22">O'Mara, Ashley</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mody%2C+Bhakti+Pradip%22">Mody, Bhakti Pradip</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mammi%2C+Marco%22">Mammi, Marco</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Simjian%2C+Thomas%22">Simjian, Thomas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ghattas%2C+Kyrellos%22">Ghattas, Kyrellos</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kaliki%2C+Srilekha%22">Kaliki, Srilekha</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Le%2C+Ngoc+Phuong+Mai%22">Le, Ngoc Phuong Mai</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liew%2C+Aaron%22">Liew, Aaron</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Migliore%2C+Mattia%22">Migliore, Mattia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mekary%2C+Rania+A%2E%22">Mekary, Rania A.</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Jan2026, Vol. 47 Issue 1, p1-11. 11p. – Name: Abstract Label: Abstract Group: Ab Data: Background: Currently, the cognitive impact of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains unclear in non-diabetic patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI), despite their widespread use for type 2 diabetes. This meta-analysis summarized cognitive outcomes from randomized controlled trials (RCTs) of GLP-1 RAs in non-diabetic patients with AD or MCI. Methods: PubMed, Cochrane Library, and Embase were searched for studies through October 27, 2024. Pooled standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated using random-effects models. Sensitivity analyses addressed variations in cognitive assessment methodologies. Between-study heterogeneity was evaluated using the I² index. Results: Four RCTs comprising 112 patients (61 placebo, 51 treatment) were included. For cognitive tests where higher scores indicate better outcomes, no significant difference was observed between GLP-1 RA and placebo groups (pooled SMD: -0.10, 95% CI: -0.53, 0.34; I² = 23.9%). Sensitivity analyses yielded consistent results. Analysis of the Alzheimer’s Disease Assessment Scale–Cognitive subscale from two studies, where lower scores indicate better outcomes, similarly showed no significant treatment effect (SMD: 0.07, 95% CI: -0.47, 0.62; I² = 0%). Conclusion: There was no evidence that GLP-1 RAs improved cognitive outcomes compared to placebo in non-diabetic patients with AD or MCI. Further research is needed to clarify their neuroprotective potential and explore alternative therapeutic strategies for cognitive decline. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=190837769 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10072-025-08602-z Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1 Titles: – TitleFull: The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer’s disease: a meta-analysis of randomized controlled trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: O'Mara, Ashley – PersonEntity: Name: NameFull: Mody, Bhakti Pradip – PersonEntity: Name: NameFull: Mammi, Marco – PersonEntity: Name: NameFull: Simjian, Thomas – PersonEntity: Name: NameFull: Ghattas, Kyrellos – PersonEntity: Name: NameFull: Kaliki, Srilekha – PersonEntity: Name: NameFull: Le, Ngoc Phuong Mai – PersonEntity: Name: NameFull: Liew, Aaron – PersonEntity: Name: NameFull: Migliore, Mattia – PersonEntity: Name: NameFull: Mekary, Rania A. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: Jan2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 15901874 Numbering: – Type: volume Value: 47 – Type: issue Value: 1 Titles: – TitleFull: Neurological Sciences Type: main |
| ResultId | 1 |
